[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:breast-carcinoma:erbb2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Breast Carcinoma","ERBB2 Gene",73,[8,16,23,30,36,42,47,53,59,65,71,77,83,89,95,100,106,112,118,124,130,135,141,147,153,159,165,171,177,182,187,193,200,206,212,218,224,230,236,241,247,253,259,265,271,277,283,289,295,301],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07205822","A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer",[12],"Phase 3","RECRUITING","2026-08-26T02:16:16.169331Z","2026-07-30T01:46:14.435695Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07102381","A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer",[20],"Phase 2","2026-08-26T02:18:23.582895Z","2026-07-05T05:32:16.733599Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07198724","ERADICATE: A Phase Ib\u002FII Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4\u002F6 Inhibitor and Endocrine-resistant HR+\u002FHER2-low or HER2-ultralow Metastatic Breast Cancer",[27],"Phase 1\u002FPhase 2","2026-08-26T02:18:00.873391Z","2026-07-05T05:32:16.660998Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07407920","Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial",[20],"2026-08-26T02:18:19.586423Z","2026-07-05T03:45:20.251405Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06185205","ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy",[20],"2026-08-26T02:17:02.694423Z","2026-05-05T02:43:29.681174Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":21,"content_modified":46},"NCT06263543","Sequencing Antibody Drug Conjugates in ER+\u002FHER2 LOW\u002FULTRA LOW MBC",[20],"2026-05-05T02:43:29.578585Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07053085","A Study of Surgery and Radiotherapy in People With Breast Cancer",[20],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:29.533955Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT05035836","A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2\u002FNeu Positive (HER2+) Breast Cancer (BC)",[20],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:29.502984Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT04893109","ATEMPT 2.0: Adjuvant T-DM1 vs TH",[20],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:29.497520Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT03769415","Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA",[],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:29.398737Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT04886531","Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers",[20],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:29.351520Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT01042379","I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",[20],"2026-08-26T02:19:28.327680Z","2026-05-05T02:43:29.200132Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT05774678","Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation",[12],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:29.021355Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":93,"content_modified":94},"NCT02945579","Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy",[],"2026-08-26T02:17:56.243868Z","2026-05-05T02:43:28.564466Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":63,"content_modified":99},"NCT06072612","Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.",[12],"2026-05-05T02:43:28.478069Z",{"nct_id":101,"title":102,"phases":103,"status":13,"updated_at":104,"content_modified":105},"NCT07506876","Concurrent Neoadjuvant Chemo\u002FEndocrine Therapy in HER2+ Breast Cancer",[20],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.342526Z",{"nct_id":107,"title":108,"phases":109,"status":13,"updated_at":110,"content_modified":111},"NCT04553770","Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer",[20],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:28.285926Z",{"nct_id":113,"title":114,"phases":115,"status":13,"updated_at":116,"content_modified":117},"NCT05950945","Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer",[12],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:28.282790Z",{"nct_id":119,"title":120,"phases":121,"status":13,"updated_at":122,"content_modified":123},"NCT06876714","ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab",[12],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:28.130354Z",{"nct_id":125,"title":126,"phases":127,"status":13,"updated_at":128,"content_modified":129},"NCT06441890","BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer",[20],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:27.988655Z",{"nct_id":131,"title":132,"phases":133,"status":13,"updated_at":81,"content_modified":134},"NCT06897488","EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial",[20],"2026-05-05T02:43:27.982803Z",{"nct_id":136,"title":137,"phases":138,"status":13,"updated_at":139,"content_modified":140},"NCT05020860","Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer",[20],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.962723Z",{"nct_id":142,"title":143,"phases":144,"status":13,"updated_at":145,"content_modified":146},"NCT05232916","Phase 3 Study to Evaluate the Efficacy and Safety of HER2\u002FNeu Peptide GLSI-100 (GP2 + GM-CSF) in HER2\u002FNeu Positive Subjects",[12],"2026-08-26T02:17:30.961790Z","2026-05-05T02:43:27.514719Z",{"nct_id":148,"title":149,"phases":150,"status":13,"updated_at":151,"content_modified":152},"NCT05325632","Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab",[20],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:27.513782Z",{"nct_id":154,"title":155,"phases":156,"status":13,"updated_at":157,"content_modified":158},"NCT06533826","TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd",[20],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:27.433128Z",{"nct_id":160,"title":161,"phases":162,"status":13,"updated_at":163,"content_modified":164},"NCT06439693","The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer",[20],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:27.429305Z",{"nct_id":166,"title":167,"phases":168,"status":13,"updated_at":169,"content_modified":170},"NCT05559164","Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted",[20],"2026-08-26T02:16:23.080181Z","2026-05-05T02:43:27.289971Z",{"nct_id":172,"title":173,"phases":174,"status":13,"updated_at":175,"content_modified":176},"NCT07459673","HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission",[20],"2026-08-26T02:15:46.655893Z","2026-05-05T02:43:27.283266Z",{"nct_id":178,"title":179,"phases":180,"status":13,"updated_at":110,"content_modified":181},"NCT03463954","Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors",[],"2026-05-05T02:43:27.091799Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":104,"content_modified":186},"NCT04329065","Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer",[20],"2026-05-05T02:43:26.929881Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT05534438","A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer",[20],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:26.664024Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":198,"content_modified":199},"NCT04521764","A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer",[197],"Phase 1","2026-08-26T02:16:54.044282Z","2026-05-05T02:35:31.754606Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT06414733","HER-2 B Cell Peptide Vaccine",[197],"2026-08-26T02:15:58.452248Z","2026-05-05T02:35:31.723910Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT04348747","Dendritic Cell Vaccines Against Her2\u002FHer3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer",[20],"2026-08-26T02:15:14.574786Z","2026-07-05T05:32:16.794666Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT05315700","Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration",[27],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.704037Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT07192432","Gene Therapy for HER-Positive Cancer (SENTRY-HER2)",[27],"2026-08-26T02:15:50.539717Z","2026-05-05T02:43:28.103874Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":228,"content_modified":229},"NCT07361562","A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors",[197],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:27.101090Z",{"nct_id":231,"title":232,"phases":233,"status":13,"updated_at":234,"content_modified":235},"NCT05523947","Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor",[27],"2026-08-26T02:16:51.982021Z","2026-04-29T02:57:57.117371Z",{"nct_id":237,"title":238,"phases":239,"status":13,"updated_at":169,"content_modified":240},"NCT06293898","Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors",[197],"2026-07-24T01:27:14.888332Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT05872295","IKS014 in Advanced Solid Tumors That Express HER2",[197],"2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.816198Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT05150691","A Phase 1\u002F2a Study of DB-1303\u002FBNT323 in Advanced\u002FMetastatic Solid Tumors",[27],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.396080Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT06695845","A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",[20],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.744064Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT03740256","Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",[197],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:28.644039Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[27],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT06760819","A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",[20],"2026-08-26T02:17:10.213717Z","2026-05-05T02:43:26.692781Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT06253871","A Phase 1\u002F1b Study of IAM1363 in HER2 Cancers",[197],"2026-08-26T02:18:31.944757Z","2026-05-05T02:35:31.700916Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT05959291","Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer",[],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:29.466970Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":191,"content_modified":294},"NCT05376878","An Investigational Scan (64Cu-DOTA-Trastuzumab PET\u002FMRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis",[293],"Phase 4","2026-05-05T02:43:29.325102Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT05933395","Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4\u002F6 Inhibitor",[20],"2026-08-26T02:15:24.145250Z","2026-05-05T02:43:29.132138Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT06833502","Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer",[20],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.708035Z"]